

1



This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious dise	ase			
Clostridium	Not applicable	A study in cell culture suggests that thuricin CD could help treat <i>Clostridium difficile</i> infections. Thuricin CD is produced by <i>Bacillus thuringiensis</i> and consists of two distinct peptides. In a panel of bacteria, thuricin CD had antibiotic activity against several types of <i>Clostridium</i> , including <i>C. difficile</i> , and against <i>Listeria monocytogenes</i> , without affecting other pathogenic and commensal bacteria. In a human distal colon model, thuricin CD significantly reduced <i>C. difficile</i> viability compared with that in untreated controls ( <i>p</i> <0.001). Next steps include developing a method to encapsulate and deliver thuricin CD ( <i>see</i> <b>Kai's story, page X</b> ).	Patented; licensed to Alimentary Health Ltd.	Rea, M.C. et al. Proc. Natl. Acad. Sci. USA; published online April 26, 2010; doi:10.1073/pnas.0913554107  Contact: R. Paul Ross, Teagasc, Moorepark Food Research Centre Fermoy, Ireland e-mail: paul.ross@teagasc.ie
		SciBX 3(18); doi:10.1038/scibx.2010.556 Published online May 6, 2010		